AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Thunder Mountain Gold to issue shares to settle $1.1M in debt
• Voya Financial estimates Q2 alternative investment pre-tax loss of $9M-$19M